Cidara Therapeutics Company Profile (NASDAQ:CDTX)

About Cidara Therapeutics

Cidara Therapeutics logoCidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CDTX
  • CUSIP:
Key Metrics:
  • Previous Close: $7.15
  • 50 Day Moving Average: $9.76
  • 200 Day Moving Average: $10.57
  • 52-Week Range: $6.65 - $15.91
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.49
  • P/E Growth: 0.00
  • Market Cap: $125.88M
  • Outstanding Shares: 16,673,000
  • Beta: 2.35
Profitability:
  • Return on Equity: -48.80%
  • Return on Assets: -45.76%
Debt:
  • Current Ratio: 9.79%
  • Quick Ratio: 9.79%
Additional Links:
Companies Related to Cidara Therapeutics:

Analyst Ratings

Consensus Ratings for Cidara Therapeutics (NASDAQ:CDTX) (?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $16.89 (123.75% upside)

Analysts' Ratings History for Cidara Therapeutics (NASDAQ:CDTX)
Show:
DateFirmActionRatingPrice TargetDetails
2/22/2017HC WainwrightReiterated RatingBuy -> Buy$25.00 -> $18.00View Rating Details
2/22/2017WBB SecuritiesUpgradeSell -> Hold$7.25View Rating Details
2/21/2017Needham & Company LLCLower Price TargetBuy$20.00 -> $10.00View Rating Details
2/21/2017WedbushReiterated RatingOutperform$13.00 -> $22.00View Rating Details
1/11/2017Cantor FitzgeraldReiterated RatingBuy$20.00View Rating Details
1/4/2017BTIG ResearchReiterated RatingPositive$24.00View Rating Details
12/21/2016Leerink SwannInitiated CoverageOutperform$17.00View Rating Details
5/14/2016Jefferies Group LLCReiterated RatingBuyView Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Cidara Therapeutics (NASDAQ:CDTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/16/2017        
8/11/2016Q2($0.76)($0.85)ViewN/AView Earnings Details
5/12/2016Q1($0.76)($0.71)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cidara Therapeutics (NASDAQ:CDTX)
Current Year EPS Consensus Estimate: $-3.22 EPS
Next Year EPS Consensus Estimate: $-3.03 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.82)($0.75)($0.78)
Q2 20163($0.85)($0.77)($0.80)
Q3 20163($0.90)($0.82)($0.86)
Q4 20163($0.95)($0.84)($0.89)
Q1 20172($1.02)($0.89)($0.96)
Q2 20172($0.86)($0.74)($0.80)
Q3 20172($0.87)($0.80)($0.84)
Q4 20172($0.69)($0.66)($0.68)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cidara Therapeutics (NASDAQ:CDTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cidara Therapeutics (NASDAQ:CDTX)
Insider Ownership Percentage: 22.20%
Institutional Ownership Percentage: 47.34%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/20/2016Jeffrey SteinCEOBuy4,310$11.51$49,608.10View SEC Filing  
5/20/2016Kevin ForrestCFOBuy4,356$11.53$50,224.68View SEC Filing  
11/25/2015Jeffrey SteinCEOBuy6,700$15.09$101,103.00View SEC Filing  
11/23/2015Kevin ForrestCFOBuy7,087$14.23$100,848.01View SEC Filing  
4/20/2015Timothy R FransonDirectorBuy4,000$16.00$64,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cidara Therapeutics (NASDAQ:CDTX)
DateHeadline
News IconCidara Therapeutics, Inc. (CDTX) Stock Price Down 3.5% on Analyst Downgrade (NASDAQ:CDTX)
ekosvoice.com - February 24 at 9:23 PM
News IconCidara Therapeutics Inc CDTX Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:CDTX)
www.bioportfolio.com - February 24 at 9:23 PM
News IconBrokers Issue New Targets On Cidara Therapeutics, Inc. (CDTX) (NASDAQ:CDTX)
eleganthomesinla.com - February 24 at 9:23 PM
News IconCidara Therapeutics, Inc. (CDTX) Upgraded to Hold by WBB Securities (NASDAQ:CDTX)
nyhetsbanken.info - February 24 at 9:23 PM
News IconAnalyst Activity - HC Wainwright Reiterates Buy on Cidara Therapeutics (NASDAQ:CDTX) (NASDAQ:CDTX)
www.graffiotech.com - February 23 at 9:13 PM
News IconCidara Therapeutics Inc (CDTX) Price Target Cut to $18.00 (NASDAQ:CDTX)
oakridgeobserver.com - February 23 at 9:13 PM
us.rd.yahoo.com logoCidara Therapeutics upgraded by WBB Securities (NASDAQ:CDTX)
us.rd.yahoo.com - February 23 at 4:11 PM
us.rd.yahoo.com logoCidara Yeast Infection Gelm Fails Phase 2 Trial (NASDAQ:CDTX)
us.rd.yahoo.com - February 23 at 4:11 PM
News IconWill Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) be growing after Earnings Report? (NASDAQ:CDTX)
eleganthomesinla.com - February 22 at 4:20 PM
streetinsider.com logoCidara Therapeutics (CDTX) Says Phase 2 RADIANT Trial of CD101 Didn't Show Sufficient Efficacy (NASDAQ:CDTX)
www.streetinsider.com - February 22 at 12:11 PM
marketexclusive.com logoAnalyst Activity – Needham & Company LLC Lowers Its Price Target On Cidara Therapeutics (NASDAQ:CDTX) to (NASDAQ:CDTX)
marketexclusive.com - February 22 at 12:11 PM
News IconCIDARA THERAPEUTICS, INC. (NASDAQ:CDTX) Files An 8-K Regulation FD Disclosure (NASDAQ:CDTX)
mundoaguaysaneamiento.net - February 22 at 12:11 PM
investopedia.com logoCidara Yeast Infection Gel Fails Phase 2 (CDTX) (NASDAQ:CDTX)
www.investopedia.com - February 22 at 12:11 PM
News IconCidara Therapeutics (CDTX) Stock: Takes A Dive On Study Failure (NASDAQ:CDTX)
cnafinance.com - February 22 at 12:11 PM
finance.yahoo.com logoCidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC (NASDAQ:CDTX)
finance.yahoo.com - February 21 at 2:26 PM
biz.yahoo.com logoCIDARA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibi (NASDAQ:CDTX)
biz.yahoo.com - February 21 at 2:26 PM
News IconCidara Therapeutics Inc CDTX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CDTX)
www.bioportfolio.com - January 8 at 9:11 PM
smarteranalyst.com logoHere’s Why Cantor Bullish on Cidara Therapeutics Inc (CDTX); Shares Rise 7% (NASDAQ:CDTX)
www.smarteranalyst.com - January 4 at 5:15 PM
publicnow.com logoCidara Therapeutics Completes Enrollment in Phase 2 RADIANT Trial Evaluating Novel Antifungal CD101 Topical in Vulvovaginal Candidiasis (NASDAQ:CDTX)
www.publicnow.com - January 4 at 5:15 PM
us.rd.yahoo.com logo8:32 am Cidara Therapeutics announces data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 in the journal Antimicrobial Agents and Chemotherapy (NASDAQ:CDTX)
us.rd.yahoo.com - December 15 at 3:14 AM
4-traders.com logoCidara Therapeutics : Newly Published Data Reinforce Growing Body of Evidence Supporting Cidara Therapeutics’ Lead Antifungal CD101 (NASDAQ:CDTX)
www.4-traders.com - December 14 at 5:10 PM
finance.yahoo.com logoNewly Published Data Reinforce Growing Body of Evidence Supporting Cidara Therapeutics’ Lead Antifungal CD101 (NASDAQ:CDTX)
finance.yahoo.com - December 14 at 5:10 PM
4-traders.com logoCidara Therapeutics : to Prese54121"81832">Cidara Therapeutics Expands Management Team (NASDAQ:CDTX)
www.4-traders.com - November 30 at 7:32 AM
finance.yahoo.com logoCidara Therapeutics’ Presentations at ASH 2016 to Highlight Potential Role of Novel Antifungal CD101 in Patients with Hematologic Malignancies (NASDAQ:CDTX)
finance.yahoo.com - November 30 at 7:32 AM
finance.yahoo.com logo8:31 am Cidara Therapeutics will present data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 at ASH 2016 (NASDAQ:CDTX)
finance.yahoo.com - November 30 at 7:32 AM
capitalcube.com logoCidara Therapeutics, Inc. :CDTX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 29, 2016 (NASDAQ:CDTX)
www.capitalcube.com - November 30 at 7:32 AM
finance.yahoo.com logoIs Cidara Therapeutics (CDTX) Stock a Solid Choice Right Now? (NASDAQ:CDTX)
finance.yahoo.com - November 25 at 4:11 PM
nasdaq.com logoCidara Provides Corporate Update and Reports Third Quarter 2016 Financial Results (NASDAQ:CDTX)
www.nasdaq.com - November 10 at 10:11 PM
4-traders.com logoCidara Therapeutics : reports 3Q loss (NASDAQ:CDTX)
www.4-traders.com - November 10 at 10:11 PM
sg.finance.yahoo.com logoCidara Therapeutics reports 3Q loss (NASDAQ:CDTX)
sg.finance.yahoo.com - November 10 at 10:11 PM
finance.yahoo.com logoCidara Therapeutics to Present Data on Novel Antifungal CD101 at the Global Joint Conference of ICHS and INFOCUS (NASDAQ:CDTX)
finance.yahoo.com - November 10 at 12:01 PM
finance.yahoo.com logoCidara Therapeutics to Present at the Stifel 2016 Healthcare Conference (NASDAQ:CDTX)
finance.yahoo.com - November 8 at 9:23 PM
News IconCidara Therapeutics Receives $20M Credit Facility from Square 1 Bank (NASDAQ:CDTX)
www.finsmes.com - November 4 at 8:38 PM
News IconCidara Announces Data From Studies Of Novel Antifungal CD101 To Be Presented At And Annual Meetings (NASDAQ:CDTX)
www.biospace.com - October 25 at 4:09 PM
businesswire.com logoCidara Therapeutics Announces Data from Studies of Novel Antifungal CD101 to be Presented at ACCP and IDWeek Annual Meetings (NASDAQ:CDTX)
www.businesswire.com - October 25 at 8:59 AM
publicnow.com logoCidara Therapeutics Announces Closing of Public Offering of Common Stock, Including Exercise of Underwriter’s Option to Purchase Additional Shares (NASDAQ:CDTX)
www.publicnow.com - October 13 at 4:02 PM
marketexclusive.com logoCidara Therapeutics Inc (NASDAQ:CDTX) Files An 8-K (NASDAQ:CDTX)
marketexclusive.com - October 10 at 4:01 PM
fxpips.com logoStocks Gapping Down Pre Market – IGLD, LPTN, ONS, MG, CDTX, GNK, SEDG (NASDAQ:CDTX)
www.fxpips.com - October 10 at 8:54 AM
streetinsider.com logoCidara Therapeutics (CDTX) Prices 2.48M Common Stock Offering at $10.10/Share (NASDAQ:CDTX)
www.streetinsider.com - October 8 at 8:52 AM
biz.yahoo.com logoCIDARA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta (NASDAQ:CDTX)
biz.yahoo.com - October 8 at 8:52 AM
finance.yahoo.com logoCidara Therapeutics Announces Pricing of Public Offering of Common Stock (NASDAQ:CDTX)
finance.yahoo.com - October 7 at 9:03 AM
finance.yahoo.com logoCidara Therapeutics Announces Commencement of Public Offering of Common Stock (NASDAQ:CDTX)
finance.yahoo.com - October 6 at 4:04 PM
marketexclusive.com logoCidara Therapeutics Inc (NASDAQ:CDTX Files an 8-k (NASDAQ:CDTX)
marketexclusive.com - October 5 at 4:25 PM
biz.yahoo.com logoCIDARA THERAPEUTICS, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off (NASDAQ:CDTX)
biz.yahoo.com - October 4 at 8:59 AM
biz.yahoo.com logoCIDARA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:CDTX)
biz.yahoo.com - September 28 at 4:00 PM
finance.yahoo.com logoCidara Therapeutics downgraded by WBB Securities (NASDAQ:CDTX)
finance.yahoo.com - September 23 at 3:33 PM
publicnow.com logoCidara Therapeutics Selects First Development Candidate from its CloudbreakTM Immunotherapy Discovery Platform (NASDAQ:CDTX)
www.publicnow.com - September 21 at 4:46 PM
publicnow.com logoCidara Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology (NASDAQ:CDTX)
www.publicnow.com - September 21 at 8:09 AM
biz.yahoo.com logoCIDARA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:CDTX)
biz.yahoo.com - September 20 at 9:59 AM
publicnow.com logoCidara Therapeutics Announces Clinical Management Team Changes (NASDAQ:CDTX)
www.publicnow.com - September 2 at 8:56 AM

Social

What is Cidara Therapeutics' stock symbol?

Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."

Where is Cidara Therapeutics' stock going? Where will Cidara Therapeutics' stock price be in 2017?

8 brokers have issued 12-month price targets for Cidara Therapeutics' shares. Their predictions range from $7.25 to $24.00. On average, they expect Cidara Therapeutics' share price to reach $16.89 in the next year.

When will Cidara Therapeutics announce their earnings?

Cidara Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March, 16th 2017.

What are analysts saying about Cidara Therapeutics stock?

Here are some recent quotes from research analysts about Cidara Therapeutics stock:

  • According to Zacks Investment Research, "Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. " (2/23/2017)

  • HC Wainwright analysts commented, "This is why there are still no topical echinocandins. Yesterday, before markets opened, Cidara reported results of the Phase 2 RADIANT study in women with vulvovaginal candidiasis (VVC) in which neither topical formulation of CD101 (gel or ointment) achieved efficacy levels comparable to standard of care (SOC) oral fluconazole. As a result, Cidara has discontinued further development of topical CD101 for VVC. The outcome of RADIANT came as a surprise to both management and us, given the potent fungicidal properties of CD101 demonstrated in vitro (even at vaginal pH of 4.0), and that both formulations had outperformed fluconazole in preclinical models' Focus now squarely on STRIVE readout in 4Q17. Recall, STRIVE is a POC Phase 2 candidemia study of CD101 IV vs. Cancidas (IV caspofungin; the leading on-market echinocandin) followed by oral fluconazole step-down (NCT02734862). Coprimary efficacy endpoints are mycological eradication (laboratory cure) and resolution of systemic signs of candidemia (clinical cure)." (2/22/2017)
  • Needham & Company LLC analysts commented, "Mgmt suggested that animal models may be less predictive than previously thought in this indication and also noted large molecular weight of echinocandins relative to azoles. Importantly, we do not believe there is any read through to efficacy of IV CD101, which is in Phase 2 testing for Invasive Candida infections. Top-line results are expected 4Q17 (unch). We reiterate BUY, but are reducing target to $10 (was $20) to reflect removal of topical CD101 from our model. We maintain a positive view of IV CD101 in invasive fungal infections and Cloudbreak platform." (2/21/2017)

Who owns Cidara Therapeutics stock?

Cidara Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (8.83%), Interwest Venture Management Co. (8.14%), Frazier Management LLC (7.87%), Perceptive Advisors LLC (4.64%), Broadfin Capital LLC (3.38%) and Eventide Asset Management LLC (1.58%). Company insiders that own Cidara Therapeutics stock include Jeffrey Stein, Kevin Forrest and Timothy R Franson.

Who sold Cidara Therapeutics stock? Who is selling Cidara Therapeutics stock?

Cidara Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Putnam Investments LLC.

Who bought Cidara Therapeutics stock? Who is buying Cidara Therapeutics stock?

Cidara Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Interwest Venture Management Co., Perceptive Advisors LLC, Broadfin Capital LLC, Alyeska Investment Group L.P., FMR LLC, State Street Corp, Russell Investments Group Ltd. and Oxford Asset Management. Company insiders that have bought Cidara Therapeutics stock in the last two years include Jeffrey Stein, Kevin Forrest and Timothy R Franson.

How do I buy Cidara Therapeutics stock?

Shares of Cidara Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cidara Therapeutics stock cost?

One share of Cidara Therapeutics stock can currently be purchased for approximately $7.55.

Cidara Therapeutics (NASDAQ:CDTX) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Cidara Therapeutics (NASDAQ:CDTX)

Earnings History Chart

Earnings by Quarter for Cidara Therapeutics (NASDAQ:CDTX)

Dividend History Chart

Dividend Payments by Quarter for Cidara Therapeutics (NASDAQ:CDTX)

Last Updated on 2/25/2017 by MarketBeat.com Staff